处方精神药物(剂量和分子的选择)的方式目前不能令人满意,这可能导致与患者长时间暴露于他或她的疾病症状和分子的副作用相关的治疗缺乏功效。为了提高治疗处方的质量,当前生物医学研究的一部分致力于开发个体化处方的药物遗传学工具。在本准则中,根据PharmGKB,我们将针对两个主要的精神药物家族:抗精神病药和抗抑郁药,按照1级临床建议提供感兴趣的基因。对于抗精神病药,有CYP2D6和CYP3A4,抗抑郁药,CYP2B6、CYP2D6和CYP2C19。这项研究将重点描述每个基因的作用,呈现导致功能变化的变体,并讨论了处方在临床实践中的意义。
The modalities for prescribing a psychotropic (dose and choice of molecule) are currently unsatisfactory, which can lead to a lack of efficacy of the treatment associated with prolonged exposure of the patient to the symptoms of his or her illness and the side effects of the molecule. In order to improve the quality of treatment prescription, a part of the current biomedical research is dedicated to the development of pharmacogenetic tools for individualized prescription. In this
guideline, we will present the genes of interest with level 1 clinical recommendations according to PharmGKB for the two major families of psychotropics: antipsychotics and antidepressants. For antipsychotics, there are CYP2D6 and CYP3A4, and for antidepressants, CYP2B6, CYP2D6, and CYP2C19. The study will focus on describing the role of each gene, presenting the variants that cause functional changes, and discussing the implications for prescriptions in clinical practice.